Home > Oncology > ESMO 2021 > Lung Cancer > Robust anticancer activity of trastuzumab deruxtecan in HER2-mutated NSCLC

Robust anticancer activity of trastuzumab deruxtecan in HER2-mutated NSCLC

Presented By
Dr Bob Li, Memorial Sloan Kettering Cancer Center, NY, USA
Conference
ESMO 2021
Trial
Phase 2, DESTINY-Lung01
Primary data from the DESTINY-Lung01 trial demonstrated trastuzumab deruxtecan (T-DXd) to be safe and effective in heavily pretreated patients with HER2-mutated non-small cell lung cancer (NSCLC). HER2 mutations occur in ∼3% of patients with NSCLC, indicating poor prognosis and an increased incidence of brain metastases [1]. T-DXd is a novel antibody-drug conjugate consisting of a humanised, anti-HER2 monoclonal antibody, a topoisomerase I inhibitor payload, and an exatecan derivative [2]. The phase 2 DESTINY-Lung01 trial (NCT03505710) assessed the efficacy and safety of T-DXd in heavily pretreated (up to 8 lines) patients with HER2-mutated NSCLC. A total of 91 patients (median age 60 years; 93.4% had a HER2 mutation; 36.3% had asymptomatic central nervous system metastasis) were treated with T-DXd (6.4 mg/kg every 3 weeks...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on